Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AG019 + teplizumab
- Development stage
- Unknown
- Lead developer
- Sanofi
- Modality
- Small Molecules, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral, Intravenous
01
Overview
AG019 + teplizumab is an investigational combination therapy for type 1 diabetes. AG019 is an oral capsule containing genetically engineered Lactococcus lactis bacteria designed to deliver human proinsulin and human interleukin-10 directly to the gut mucosa. This approach aims to induce antigen-specific immune tolerance by promoting regulatory T cell responses and reducing autoimmune destruction of pancreatic beta cells. Teplizumab is a humanized monoclonal antibody targeting CD3 on T lymphocytes; it modulates the immune response by deactivating autoreactive T cells involved in beta cell destruction. The combination seeks to synergistically preserve endogenous insulin production in newly diagnosed or early-stage type 1 diabetes patients[2][3][4][7].
- Other names
- AG019 ActoBioticsAG-019 ActoBioticsAG 019 ActoBioticsteplizumab-mzwv
02
Targets
CD3 (T-cell surface glycoprotein CD3)IL10RA (Interleukin-10 Receptor)Proinsulin-specific T cell receptor
Beyond the preview
Go deeper on AG019 + teplizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AG019 + teplizumab.